Teva Pharmaceutical on Tuesday completed its $40 billion acquisition of the generics arm of rival Allergan, a move the Israeli firm hailed as confirmation of its intention to become one of the world's largest drugmakers.
"Teva Pharmaceutical Industries Ltd. and Allergan plc today announced that Teva has completed its acquisition of Allergan's generics business (Actavis Generics)" the Israeli company said in a statement.
Read more